While doctors understand that adolescents have certain unique health questions and concerns, several challenges prevent this critical information from being collected in a systematic way and providing appropriate referrals across a wide group of patients.
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound | Psychedelic Invest
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly